Statins and Macular Degeneration
This study, presented at ARVO 2026, suggests that high-intensity statin therapy significantly lowers the risk of progression from intermediate to "wet" age-related macular degeneration (AMD). Researchers believe statins may slow the buildup of drusen—lipid-rich deposits under the retina—similar to how they manage plaques in heart disease.
Key Study Findings
Over a 30-month follow-up of 124 patients, the researchers observed:
Reduced Risk: Statin users had a 46% lower risk of overall AMD progression compared to non-users.
Wet AMD Prevention: High-intensity statin use specifically reduced the risk of converting to neovascular (wet) AMD by 70%.
Vision Preservation: High-intensity users were 59% less likely to suffer significant visual acuity loss and showed better preservation of contrast sensitivity.
Drusen Impact: Treatment was associated with a slower increase in drusen volume, though it did not appear to impact progression toward geographic atrophy (dry AMD).
Clinical Implications
The findings indicate that for patients already taking statins for cardiovascular health, the medication may offer a "double benefit" by protecting visual function. Doctors may eventually incorporate intensive statin protocols as a broader strategy to prevent advanced vision loss in at-risk populations.
Comments
Post a Comment
Leave a Comment or Question: